Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Elevated blood sugar levels linked with increased risk of colorectal cancer

Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.

30 Nov 2011

Repeated heading of a soccer ball increases risk for brain injury, cognitive impairment

Using advanced imaging techniques and cognitive tests, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center , the University Hospital and academic medical center for Einstein, have shown that repeatedly heading a soccer ball increases the risk for brain injury and cognitive impairment.

29 Nov 2011

Serotonin instructs scar forming cells to switch off regeneration in chronic liver disease

In liver disease, extent of tissue damage depends on the balance between the generation of scar tissue and the regeneration of new liver cells. In a significant minority of people who get injury to their organs instead of repairing them, they form scars.

29 Nov 2011

Einstein, Montefiore experts available to discuss effects of radiation dose and exposure

Experts from Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University are available for interviews on topics ranging from effects of radiation dose and exposure to MRI imaging to detect brain damage in soccer players due to "heading" and cancer post-treatment imaging during the annual Radiological Society of North America Scientific Assembly.

24 Nov 2011

Non-alcoholic fatty liver disease does not appear to affect survival

Non-alcoholic fatty liver disease (NAFLD) is a common condition associated with obesity and heart disease long thought to undermine health and longevity. But a new study by Johns Hopkins researchers suggests the condition does not affect survival.

22 Nov 2011

Researchers manipulate life span of yeast by mutating chemical residues

Collaborations between Johns Hopkins and National Taiwan University researchers have successfully manipulated the life span of common, single-celled yeast organisms by figuring out how to remove and restore protein functions related to yeast aging.

22 Nov 2011

American high school students earn top honors for liver disease and brain injury research

The shortlist of contenders for the highest science honor awarded to American high school students narrowed tonight as the winners of the Siemens Competition in Math, Science & Technology Region 3 Finals were announced.

21 Nov 2011

Senator Klein opens new Cognitive Neurophysiology Laboratory at Albert Einstein College of Medicine

New York State Senator Jeffrey D. Klein joined administrators and faculty members of Albert Einstein College of Medicine of Yeshiva University last Friday to officially open their new Cognitive Neurophysiology Laboratory.

19 Nov 2011

Cancer cells tap into natural recycling system to obtain energy

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that cancer cells tap into a natural recycling system to obtain the energy they need to keep dividing. In a study with potential implications for cancer treatments, Einstein researchers used genetic manipulation to turn off this recycling system within the walls of cells and stop both tumor growth and metastasis.

17 Nov 2011

Leading alcohol researchers to discuss latest genetic findings at Loyola meeting

Leading alcohol researchers from the United States and Canada will discuss their latest findings at an all-day meeting Nov. 18 at Loyola University Chicago Stritch School of Medicine.

16 Nov 2011

N.Y. State Senator opens Einstein's new Cognitive Neurophysiology Lab

16 Nov 2011

Dramatic rise in obesity, fatty liver disease increases need for transplants

The dramatic rise in obesity is leading to more fatty liver disease in the United States, increasing the need for more transplants at a time when there already is a severe shortage of donated organs.

11 Nov 2011

N-acetylcysteine plus cortisone shows promise against acute alcoholic hepatitis

Acute alcoholic hepatitis is one of the most serious forms of alcoholic liver disease, affecting individuals with chronic excessive alcohol consumption, which generally equates to more than 50 grams of alcohol per day, over a period of more than three to six months. The disease is characterized by liver failure and acute jaundice (icterus), which may induce a coma through liver failure and an ensuing death rate of between 40-45% within the first six months.

11 Nov 2011

Researchers uncover mechanism that governs cell specialization

Researchers at then Albert Einstein College of Medicine of Yeshiva University have uncovered a mechanism that governs how cells become specialized during development.

10 Nov 2011

Drug effectively combats obesity in “couch potato” monkeys” Study

According a new study an experimental anti-cancer drug could help fight obesity. The drug chokes off the blood supply to fat cells and helped obese monkeys slim down in the experiments.

10 Nov 2011

Positive results from Alkermes VIVITROL addiction study

Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress in Las Vegas, NV.

10 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

Second molecular conductor discovered in some children with biliary atresia

Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011